Trial Condition(s):

Multiple Sclerosis

RETAIN: Real world Evidence assessment of inTerferon beta-1b Adherence using autoINjectors (RETAIN)

Bayer Identifier:

20750

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Primary objective(s):
•    To describe medication possession ratio (MPR) and persistence rates over the 24-month period prior to (pre-BETACONNECT) and the 24-month period following the introduction and uptake of the BETACONNECT device (post-BETACONNECT) for patients with MS using Betaseron or Rebif.
Secondary objective(s):
•    To describe baseline demographic and clinical characteristics in the populations of interest.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
1216
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, United States

Status
Completed
 

For details, please refer to trial results

Additional Information

Not Available